Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making
Files
Publication date
2016-04
Authors
Franken, M. D.
Koopman, Miriam
Van Oijen, Martijn
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cetuximab, Clinical Decision-Making, Colorectal Neoplasms, Cost-Benefit Analysis, Fluorouracil, Leucovorin, Quality-Adjusted Life Years, Letter, Taverne
Citation
Franken, M D, Koopman, M & van Oijen, M G H 2016, 'Cetuximab as First-line Treatment for Metastatic Colorectal Cancer : Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making', American Journal of Clinical Oncology, vol. 39, no. 2, pp. 214. https://doi.org/10.1097/COC.0000000000000253